Login to Your Account



Chi-Med advancing fruquintinib into phase III trial in gastric cancer

By Pearl Liu
Staff Writer

Friday, November 3, 2017

HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) said the phase III trial of its oral vascular endothelial growth factor (VEGF) inhibitor fruquintinib has begun.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription